Pharsight

Pepcid Ac generic

Pepcid Ac is an acid-reducing drug owned by J And J Consumer Inc. It contains the active ingredient famotidine and was first authorized for market use on 24 September 1998. The drug comes in a chewable oral tablet format. Pepcid Ac holds a single drug patent that has already expired.

When will Pepcid Ac generic be available?

The patent for Pepcid Ac has already expired, specifically on 26 February 2022, making it feasible for the release of Pepcid Ac generics in the market. The last patent, labeled as US6814978*PED, was regarding the process for preparing a soft tablet.

Pepcid Ac uses

Pepcid Ac is used to manage conditions related to the stomach and intestine such as ulcers and gastroesophageal reflux disease (GERD). Its active ingredient, famotidine, works by decreasing the amount of acid the stomach produces, thus providing relief from heartburn and preventing ulcers.

Pepcid Ac patent expiration

Pepcid Ac had one drug patent, US6814978*PED, concerned with the process for preparing a soft tablet. This patent expired on February 26, 2022. Below are the details of the patent:

Pepcid Ac dosage

Want to ask something?